Pre-exposure prophylaxis (PrEP) by U.S. residents against HIV infection has resulted in positive outcomes. Incidence of new HIV infections among those 13 years old and above fell during 2012 - 2016, and this plunge presented a statistically noteworthy association with an increase in drug prophylaxis among U.S. residents in the same duration.
96-week data on doravirine, Merck’s HIV drug, was posted by the drugmaker recently. Merck expects it to outrun drugs like Bristol-Myers Squibb’s Sustiva in combination regimens and antiretroviral drugs from AbbVie and Johnson & Johnson in viral suppression.
The 2018 Recommendations of the International Antiviral Society-USA (IAS-USA) suggests that early treatment in adult HIV patients brings about rapid and more definite decrease in viral load and better care of the patient.
Current HIV drugs usually act on enzymes needed by the virus throughout its survival. But no drug targets the outermost layer of the virus named the capsid, which protects the genetic material delivered into the host.
The research work under the lead investigator Amy Zheng of the Massachusetts General Hospital (MGH) Medical Practice Evaluation Center in Boston indicated that the Dolutegravir-based regimen would increase the life expectancy of HIV victims by 2.8 years and prevent 13,000 new HIV infections over 5 years. It was also revealed that this first-line treatment would be cost-effective in 2 years and cost-saving over 5 years.
In 2015, it was reported that around 36.7 million people throughout the world were affected with AIDS, among which 1.1 million were stated as deceased. The majority of AIDS cases were recorded in various African countries followed by India.
An ultimate focus on a specific protein named myostatin has led to the discovery of a muscle building pill, that could easily reduce gym visits. Suppression of myostatin production could increase healthier muscle mass, which would act as markers in improving kidney and heart health.
It has been stated by the patients that Gilead concealed crucial information that the TDF drugs could trigger kidney and bone risks. A safer alternative in the form of TAF could have been incorporated while marketing Truvada and Atripla. The research into TAF was deliberately stopped and the drugs are not likely to be brought to the shelf in the near future.
ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a Positive Opinion recommending marketing authorisation for Juluca (dolutegravir/rilpivirine) for the treatment of HIV infection in adults
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.
WordPress database error: [Table 'wp_posts' is marked as crashed and should be repaired]
SELECT SQL_CALC_FOUND_ROWS wp_posts.ID FROM wp_posts LEFT JOIN wp_term_relationships ON (wp_posts.ID = wp_term_relationships.object_id) WHERE 1=1 AND (
wp_term_relationships.term_taxonomy_id IN (1,54)
) AND wp_posts.post_type = 'post' AND (wp_posts.post_status = 'publish') GROUP BY wp_posts.ID ORDER BY wp_posts.post_date DESC LIMIT 0, 10